Evidence map›Paper›PMID 36505492›Full record

Observational studyFrontiers in immunology2022

Sustained viral response and relapse after discontinuation of oral antiviral drugs in HBeAg-positive patients with chronic hepatitis B infection.

Fangfang Sun, Zhenhua Li, Leiping Hu, Wen Deng, Tingting Jiang, Shiyu Wang, Xiaoyue Bi, Huihui Lu, Liu Yang, Yanjie Lin and 14 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 78% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Review
  2. Serum miR-146a and miR-155 as Predictors of Virological Control After Entecavir Withdrawal in HBeAg-Positive Chronic Hepatitis B Patients.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 1 country.

Fangfang SunDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Zhenhua LiDepartment of Gynecology and Obstetrics, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Leiping HuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Wen DengDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Tingting JiangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Shiyu WangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Xiaoyue BiDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Huihui LuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Liu YangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Yanjie LinDepartment of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing, China.
Zhan ZengDepartment of Hepatology Division 2, Peking University Ditan Teaching Hospital, Beijing, China.
Ge ShenDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Ruyu LiuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Min ChangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Shuling WuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Yuanjiao GaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Hongxiao HaoDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Mengjiao XuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Xiaoxue ChenDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Lu ZhangDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Yao LuDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Jianping DongDepartment of Infectious Diseases, Haidian Hospital, Beijing Haidian Section of Peking University Third Hospital, Beijing, China.
Yao XieDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Minghui LiDepartment of Hepatology Division 2, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Capital Medical University · CNBeijing Ditan Hospital · CNBeijing Haidian Hospital · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To investigate the sustained virological response and relapse in chronic hepatitis B (CHB) patients with hepatitis B e antigen (HBeAg) positive after stopping oral antiviral drugs, and to monitor the disease progression and the incidence of adverse events such as liver cirrhosis and hepatocellular carcinoma. Methods: This is a prospective observational study. Patients who continued nucleos(t)ide analogue (NA) treatment after achieving HBeAg seroconversion for more than 3 years were enrolled. After signing the informed consent form, patients stopped NA treatment and received follow-up. During the follow-up, the antiviral treatment information of the patients was collected, and the follow-up observation was carried out every 3 months since the enrollment. We monitored the virological indexes, liver and kidney function, serology and liver imaging during follow-up. The purpose of this study was to explore the sustained virological response rate, HBV DNA recurrence rate, clinical relapse rate and the related factors after drug withdrawal. Results: A total of 82 patients were enrolled, including 42 males (51.22%) and 40 females (48.78%), with a median age of 34.00 (31.00, 37.25) years. All enrolled patients were followed up for 1 year. At the end of the follow-up, 36.59% (30/82) of patients had sustained virological response, 63.41% (52/82) of patients had HBV DNA reactivation, 17.07% (14/82) of patients had clinical relapse, and 10.98% (9/82) of patients had HBeAg reversion. During the follow-up, there were no adverse events such as liver cirrhosis and hepatocellular carcinoma. The median level of hepatitis B surface antigen (HBsAg) in patients with sustained virological response was lower than that in patients with HBV DNA reactivation (2.92 vs.3.18 log Conclusion: The sustained virological response rate of HBeAg positive CHB patients after stopping oral antiviral treatment is lower, and it is more common in patients with lower HBsAg levels. Patients still need to be closely monitored after stopping NA therapy.

Indexed as

Carcinoma, HepatocellularHepatitis BHepatitis B, ChronicLiver NeoplasmsAdultAntiviral AgentsChronic DiseaseDNA, ViralFemaleHepatitis B e AntigensHepatitis B Surface AntigensHumansLiver CirrhosisMaleAntiviral AgentsDNA, ViralHepatitis B e AntigensHepatitis B Surface Antigenschronic hepatitis Bclinical relapseHBeAgHBV DNAnucleos(t)ide analoguesustained virological response

Identifiers

PMID36505492
PMCPMC9732422
OpenAlexW4310039770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.